Clinical trials: Neoadjuvant Treatment
Ib-IIIb NSCLC
Monitoring the Efficacy of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC by Sequencing of Immune Receptor Repertoire: a Prospective, One Arm Clinical Study
To observe and evaluate the efficacy and safety of Duvalizumab Combined With Neoadjuvant Chemotherapy for Ib-IIIb NSCLC and the relevance with Immune Receptor Repertoire
- Trial name
- NCT04897386
- Testing
- Duvalizumab
- Volunteers
- 30 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
HCC - Hepatocellular Carcinoma
An Exploratory Clinical Study on Neoadjuvant Treatment of Hepatocellular Carcinoma with QL1706 Combined with Lenvatinib
This is a single-center, single-arm, prospective trial to explore the efficacy and safety of neoadjuvant treatment with Iparomlimab and Tuvonralimab Injection combined with lenvatinib in patients with advanced HCC
- Trial name
- NCT06884982
- Testing
- QL1706 Plus Lenvatinib
- Volunteers
- 30 people
- Sponsor
- Northern Jiangsu People's Hospital
Colitis, Ulcerative
An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis
The purpose of this study is to assess the effects (good and bad) of golimumab (CNTO 148) therapy in participants with ulcerative colitis (UC).
- Trial name
- NCT00487539
- Testing
- Golimumab 100 mg, Golimumab 200 mg, Golimumab 400 mg
- Where
- 200 sites in United States, Australia and 23 more
- Volunteers
- 1,065 people
- Sponsor
- Janssen Research & Development, LLC
Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor
Treating Muscle-invasive Bladder Cancer With A Non-surgical Method Consisting of Anti-PD-1 Therapy and Chemoradiation
The goal of this Phase 2 trial is to evaluate a non-surgical bladder-preserving treatment mode which consists of neoadjuvant chemotherapy plus anti-programmed cell death protein 1 (anti-PD-1) therapy followed by radiotherapy plus…
- Conditions
- Muscle-Invasive Bladder Carcinoma, Programmed Cell Death Protein 1 Inhibitor, Radiotherapy
- Trial name
- BCIRT-01 (NCT05975307)
- Testing
- Toripalimab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Sun Yat-sen University
Locally Advanced Nasopharyngeal Carcinoma
Timing Optimization of Immunotherapy During Neoadjuvant Chemotherapy for Locally Advanced Nasopharyngeal Carcinoma
This is a multicenter, open-label, randomized phase II clinical trial designed to evaluate the optimal timing of toripalimab administration during neoadjuvant chemotherapy in patients with locoregionally advanced nasopharyngeal…
- Trial name
- NCT07388836
- Testing
- Toripalimab
- Volunteers
- 198 people
- Sponsor
- Fujian Cancer Hospital
Locally Advanced Rectal Adenocarcinoma
INNATE: Immunotherapy During Neoadjuvant Therapy for Rectal Cancer
Determine the complete pathologic complete response (pCR) rate in patients with locally advanced rectal adenocarcinoma.
- Trial name
- NCT04130854
- Testing
- APX005M, mFOLFOX, and Radiation Therapy 5Gy x 5 days, mFOLFOX and Radiation Therapy 5Gy x 5 days
- Where
- 4 sites in United States
- Volunteers
- 58 people
- Sponsor
- University of Texas Southwestern Medical Center
Health Care Quality, Health Care Evaluation
A Study Comparing Imatinib and Imatinib/Pegylated Interferon in Chronic Myeloid Leukemia
Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly.
- Trial name
- NCT01227356
- Testing
- imatinib and pegylated interferon
- Where
- 3 sites in Sweden
- Volunteers
- 112 people
- Sponsor
- Uppsala University
Prostate Cancer
Luteinizing Hormone-Releasing Hormone Agonist Therapy and Iodine I 125 Implant in Treating Patients With Previously Untreated Prostate Cancer
RATIONALE: Androgens can cause the growth of prostate cancer cells. Luteinizing hormone-releasing hormone agonists may lessen the amount of androgens made by the body.
- Trial name
- SHIP0804 (NCT00664456)
- Testing
- Adjuvant therapy, Neoadjuvant therapy, Brachytherapy（iodine I 125）
- Where
- Japan
- Volunteers
- 421 people
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Metastatic Colorectal Cancer, MSS
Chemotherapy Plus Bevacizumab and Anti-PD-1 Followed by Induction Therapy of Chemotherapy Plus Bevacizumab
Fluorouracil and oxaliplatin-based combined with molecular targeted drugs are still the main treatment strategies for patients with advanced metastatic colorectal cancer (mCRC).
- Trial name
- NCT06415851
- Testing
- mFOLFOX6 regimen + bevacizumab + PD-1 monoclonal antibody
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Zhangfa Song
Renal Cell Carcinoma
A Study of Cemiplimab and Fianlimab in People With Clear Cell Renal Cell Carcinoma
The researchers are doing this study to find out whether it is practical (feasible) to give cemiplimab and fianlimab before a nephrectomy and whether it causes any delays with surgery in people with kidney cancer.
- Trial name
- NCT06699602
- Testing
- Cemiplimab, Fianlimab
- Where
- 7 sites in United States
- Volunteers
- 10 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Urinary System Tumor
A Study of Cadonilimab（AK104）Combined With Standard Treatment for Function Preservation in Urinary System Tumors
This is an open label, dual cohort ,phase II study to explore efficacy and safety of cadonilimab(PD-1/CTLA-4 Bispecific Antibody) combined with standard regimen neoadjuvant treatment in urothelial carcinoma（UC） and renal cell…
- Trial name
- NCT06427057
- Testing
- Cadonilimab plus chemotherapy, Cadonilimab plus TKI
- Volunteers
- 40 people
- Sponsor
- Tongji Hospital
Ovarian Cancer, Fallopian Tube Cancer
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a 1:1 randomized, open label, multi-center phase I/II trial to evaluate the safety, dosing, efficacy, and biological activity of adding IMNN-001 to chemotherapy + BEV compared to chemotherapy + BEV alone.
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
- Trial name
- MRD (NCT05739981)
- Testing
- Paclitaxel, Carboplatin, Bevacizumab
- Where
- 4 sites in United States
- Volunteers
- 30 people
- Sponsor
- Imunon
Acute Myeloid Leukemia (AML), CEBPA Mutation
Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML
The goal of this clinical trial is to learn if a treatment combination-venetoclax plus hypomethylating agents (like azacitidine or decitabine) and low-dose cytarabine-works to treat adults with newly diagnosed CEBPA-mutated acute…
- Conditions
- Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML
- Trial name
- NCT07451912
- Testing
- Venetoclax + Hypomethylating Agents + Low-Dose Cytarabine for CEBPA-Mutated AML (Unfit Patients)
- Where
- China
- Volunteers
- 29 people
- Sponsor
- The First Affiliated Hospital of Soochow University
Rectal Cancer
Preoperative IMRT With Concurrent High-dose Vitamin C and mFOLFOX6 in Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the safety and efficacy of preoperative chemoradiotherapy (IMRT) with concurrent high-dose intravenous vitamin C and mFOLFOX6 in locally advanced rectal cancer patients.
- Trial name
- CORT (NCT04801511)
- Testing
- Vitamin C
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhou Fuxiang
NSCLC
Penpulimab Combined With Anlotinib in Neoadjuvant Treatment of Resectable Non-small Cell Lung Cancer
Neoadjuvant therapy with penpulimab combined with anlotinib;with surgery within 4-6 weeks after drug withdrawal;Adjuvant therapy within 4-12 weeks after surgery
- Trial name
- pcwaintrl (NCT05387109)
- Testing
- penpulimab combined with anlotinib
- Volunteers
- 41 people
- Sponsor
- Tang-Du Hospital
Breast Cancer
Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer
Primary objective of the study in patients without a sufficient sonographic response (i.e. iNC) to 2 cycles of TAC as preoperative treatment of operable (T>/= 2cm, N0-2,M0) primary breast cancer: To determine the response rate…
- Trial name
- GeparTrio (NCT00544765)
- Testing
- TAC, NX
- Volunteers
- 2,014 people
- Sponsor
- GBG Forschungs GmbH
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8
Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer
This clinical trial studies the effects of a dietary intervention prior to surgery (neoadjuvant) in patients with intermediate risk prostate cancer. Changing your diet before surgery may help to improve overall health.
- Conditions
- Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8
- Trial name
- NCT04985565
- Testing
- Dietary Intervention, Radical Prostatectomy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- M.D. Anderson Cancer Center
Resectable Locally Advanced Non-small Cell Lung Cancer
Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043)
This is a multicenter, randomized, open label, phase II study.
- Trial name
- ALTER-L043 (NCT04846634)
- Testing
- Penpulimab+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib+Cisplatin/Carboplatin+Pemetrexed/Paclitaxel/Gemcitabine/Docetaxel, Penpulimab+Anlotinib
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy
Neoadjuvant Apatinib Combined With Sintilimab and Perioperative SOX Versus Neoadjuvant Sintilimab Combined With Perioperative SOX for Intestinal Type of Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma
This study aims to compare the efficacy and safety of neoadjuvant apatinib combined with sintilimab and perioperative SOX chemotherapy versus neoadjuvant sintilimab combined with perioperative SOX chemotherapy in locally advanced…
- Conditions
- Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Neoadjuvant Therapy, Adjuvant Chemotherapy, pCR Rate
- Trial name
- NCT06925243
- Testing
- Neoadjuvant apatinib combined with sintilimab and perioperative SOX, Neoadjuvant sintilimab combined with perioperative SOX
- Where
- 4 sites in China
- Volunteers
- 682 people
- Sponsor
- Zuoyi Jiao
Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia
Dexamethasone Compared With Prednisone During Induction Therapy and Methotrexate With or Without Leucovorin During Maintenance Therapy in Treating Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia
This randomized phase III trial is studying dexamethasone to see how well it works compared to prednisone during induction therapy.
- Conditions
- Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia, Childhood B Acute Lymphoblastic Leukemia
- Trial name
- NCT00075725
- Testing
- Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride
- Where
- 234 sites in United States, Australia and 3 more
- Volunteers
- 3,154 people
- Sponsor
- Children's Oncology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.